首页> 外文期刊>Child Neurology Open >De Novo Interstitial Deletion of 9q in a Pediatric Patient With Global Developmental Delay
【24h】

De Novo Interstitial Deletion of 9q in a Pediatric Patient With Global Developmental Delay

机译:具有全球发育延迟的儿科患者9Q的Novo全口腔删除

获取原文
       

摘要

Cytogenomic microarray (CMA) methodologies, including array comparative genomic hybridization (aCGH) and single-nucleotide polymorphism-detecting arrays (SNP-array), are recommended as the first-tier test for the evaluation of imbalances associated with intellectual disability, autism, and multiple congenital anomalies. The authors report on a child with global developmental delay (GDD) and a de novo interstitial 7.0 Mb deletion of 9q21.33q22.31 detected by aCGH. The patient that the authors report here is noteworthy in that she presented with GDD and her interstitial deletion is not inclusive of the 9q22.32 locus that includes the PTCH1 gene, which is implicated in Gorlin syndrome, or basal cell nevus syndrome (BCNS), has not been previously reported among patients with a similar or smaller size of the deletion in this locus suggesting that the genomic contents in the identified deletion on 9q21.33q22.31 is critical for the phenotype.
机译:三种方法,包括阵列对比基因组杂交(ACGH)和单核苷酸多态性检测阵列(SNP阵列)的细胞素微阵列(CMA)方法被推荐为评估与智力残疾,自闭症和识别性的失调的第一层测试多个先天性异常。作者报告了一个具有全球发展延迟(GDD)的儿童和ACGH检测到的9Q21.33Q22.31的DE Novo Interterial 7.0 MB删除。提交人报告的患者值得注意的是,她呈现GDD和她的间质缺失并不包含包含PTCH1基因的9Q22.32基因座,其涉及巨曲线综合征或基础细胞痣综合征(BCNS),此前尚未报道在该基因座中缺失相似或更小的缺失患者的患者,表明在9Q21.33 Q22.31上鉴定的缺失中的基因组内容对于表型至关重要。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号